About Roxro Pharma
Roxro Pharma is a Healthcare company based in Menlo Park (United States) founded in 1999, and was acquired by Luitpold in December 2010. Acute pain drugs are developed from acquired failed candidates. Roxro Pharma has raised $42.7 million across 1 funding round from investors including Thomas Weisel Partners, Luitpold and Prospect Venture Partners. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its legal entity is Roxro Pharma Inc. Its competitors include Flexion Therapeutics, Eliem Therapeutics and Zogenix; 3 of its 3 listed competitors have raised funding.
Company details
Roxro Pharma develops drugs for pain treatment. The company acquires discarded or failed drugs from other companies and pushes them through clinical development. Roxro obtained FDA approval for SPRIX Nasal Spray, an intranasal formulation for the treatment of dental and postoperative pain. Other products include: ROX-828, a non-opioid and non-triptan intranasal product for the treatment of migraine. The company was acquired by Luitpold Pharmaceuticals, a USA-based subsidiary of Japanese drug major Daiichi Sankyo.
- Headquarters Menlo Park, United States
- Stage Acquired
- SectorsHealthcare
- Website roxropharma.com
- Social LinkedIn
- Acquired by Luitpold (Dec 2010)
- Legal Name Roxro Pharma Inc
- Total Equity Funding$42.7M (USD)
in 1 rounds
- Latest Funding Round$42.7M (USD), Series B
Jun 2007
- InvestorsThomas Weisel Partners
& 3 more
- Acquired byLuitpold
(Dec 2010)
Funding Insights of Roxro Pharma
Roxro Pharma has successfully raised a total of $42.7M through 1 strategic funding round. The most recent funding activity was a Series B round of $42.7 million completed in June 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42.7M
- Total Rounds 1
- Last Round Series B — $42.7M
- First Round $42.7M
(Jun 2007)
- Investors Count 3
All 1 funding rounds of Roxro Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2007 | $42.7M | Series B | – | – |
4 investors in total: 4 institutional.
Investors in Roxro Pharma
Roxro Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Thomas Weisel Partners, Luitpold and Prospect Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in US life sciences and healthtech firms. | prospectventures.com | Palo Alto, United States | ||
VC firm investing in the US | shv.com | Palo Alto, United States | ||
Wealth management services are provided to high-net-worth clients. | 1999 | tweisel.com | San Francisco, United States | |
Traditional pharma company engaged in development and marketing of variety of pharmaceutical products and medical devices | 1910 | luitpold.com | New York, United States |
Investor details for Roxro Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Roxro Pharma
3 dated milestones of Roxro Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Roxro Pharma is founded.
- Funding First funding round of $42.7M.
- Exit Acquired by Luitpold.
Competitors of Roxro Pharma
Roxro Pharma has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Eliem Therapeutics and Zogenix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. |
Detailed competitors of Roxro Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pain Management
3 companies that operate in the same segment as Roxro Pharma (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Roxro Pharma
Roxro Pharma was founded in 1999 and raised its 1st funding round 8 years after it was founded.
Roxro Pharma is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Roxro Pharma is a funded company, having raised a total of $42.7M across 1 funding round to date. The company's 1st funding round was a Series B of $42.7M, raised on Jun 2007.
Roxro Pharma develops drugs for pain treatment. The company acquires discarded or failed drugs from other companies and pushes them through clinical development. Roxro obtained FDA approval for SPRIX Nasal Spray, an intranasal formulation for the treatment of dental and postoperative pain. Other products include: ROX-828, a non-opioid and non-triptan intranasal product for the treatment of migraine. The company was acquired by Luitpold Pharmaceuticals, a USA-based subsidiary of Japanese drug major Daiichi Sankyo.
Roxro Pharma's top competitors include Flexion Therapeutics, Zogenix and Eliem Therapeutics.
Roxro Pharma has 4 investors. Key investors include Thomas Weisel Partners, Luitpold, Prospect Venture Partners, and Sutter Hill Ventures.
Roxro Pharma operates through Roxro Pharma Inc.
Yes. Roxro Pharma was acquired by Luitpold in December 2010.